{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for l root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT02108756: Not Applicable Interventional Unknown status Bleeding Gastric Ulcer
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
Front Immunol. 2019;10:1275.: Not Applicable Human clinical trial Completed Psoriasis/blood/immunology
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02993250: Phase 2 Interventional Completed Hepatitis C, Chronic
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02490891: Phase 2 Interventional Unknown status Lymphoma
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
FLOTEGATIDE is a cyclic tripeptide with arginine-glycine-aspartic acid (R-G-D) motif. Its 18F radiolabelled form is a positron emission tomography (PET) tracer targeting integrin alpha-V/beta-3.
Status:
Investigational
Source:
NCT04334317: Phase 2 Interventional Completed Parkinson Disease
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03847467: Phase 1/Phase 2 Interventional Recruiting Inflammatory Bowel Diseases
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01593735: Phase 1 Interventional Completed Hepatitis C
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-2748 is hepatitis C Virus NS3/4a Protease Inhibitor patented by pharmaceutical company Merck & Co Co for the treatment of hepatitis C virus infection.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Fasidotril is a diester prodrug of the active metabolite fasidotrilat. Fasidotrilat inhibited both angiotensin I converting enzyme (ACE, EC 3.4.25.1) and neprilysin (NEP, EC 3.4.24.11, also named neutral endopeptidase, enkephalinase, or atriopeptidase) at nanomolar concentrations (Ki = 9.8 nM
against ACE and 5.1 nM against NEP)
Fasidotril was being developed for the treatment of myocardial infarction, congestive heart failure and myocardial infarction.
Status:
Investigational
Source:
NCT02561000: Phase 2 Interventional Completed Arterial Occlusive Diseases
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
PZ-128 (also known as P1pal7 ) is a cell-penetrating pepducin inhibitor of PAR1 that targets the receptor-G-protein interface on the inside surface of platelets. In preclinical studies, PZ-128 suppresses PAR1 aggregation and arterial thrombosis in guinea pigs and baboons and strongly synergized with oral clopidogrel. PZ-128 shows potent anti-metastatic and anti-angiogenic activity in Breast, Ovarian, and Lung Cancer preclinical studies. In clinical trials, PZ-128 shows a promising antiplatelet activity that provides rapid, specific, dose-dependent, and reversible inhibition of platelet protease-activated receptor-1 through a novel intracellular mechanism.
